KIMBERLY GLASS: Open Payments
NPI 1497119101 · GRIFFIN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$433 in 22 payments from 13 companies in 2025. Trend: 2023 $634 · 2024 $510 · 2025 $433
Food & beverage: $433
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $72 |
| Novo Nordisk Inc | 3 | $65 |
| Sumitomo Pharma America, Inc. | 3 | $50 |
| ABBVIE INC. | 2 | $44 |
| GlaxoSmithKline, LLC. | 2 | $40 |
| PFIZER INC. | 2 | $32 |
| Noven Therapeutics, LLC | 1 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| Amgen Inc. | 1 | $18 |
Products named: AIRSUPRA, GEMTESA, Wegovy, ELIQUIS, QULIPTA, Xelstrym, Veozah, Ozempic.
Industry payments across GA — which companies pay providers there.
